The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles
Open accessAbstract
There has been considerable progress recently towards developing therapeutic strategies for Huntington's disease (HD), with several compounds showing beneficial effects in transgenic mouse models. However, human trials in HD are difficult, costly and time-consuming due to the slow disease course, insidious onset and patient-to-patient variability. Identification of molecular biomarkers associated with disease progression will aid the development of effective therapies by allowing further validation of animal models and by providing hopefully more sensitive measures of disease progression. Here, we apply metabolic profiling by gas chromatography-time-of-flight-mass spectrometry to serum samples from human HD patients and a transgenic mouse model in a hypothesis-generating search for disease biomarkers. We observed clear differences in metabolic profiles between transgenic mice and wild-type littermates, with a trend for similar differences in human patients and control subjects. Thus, the metabolites responsible for distinguishing transgenic mice also comprised a metabolic signature tentatively associated with the human disease. The candidate biomarkers composing this HD-associated metabolic signature in mouse and humans are indicative of a change to a pro-catabolic phenotype in early HD preceding symptom onset, with changes in various markers of fatty acid breakdown (including glycerol and malonate) and also in certain aliphatic amino acids. Our data raise the prospect of a robust molecular definition of progression of HD prior to symptom onset, and if validated in a genuinely prospective fashion these biomarker trajectories could facilitate the development of useful therapies for this disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toxic Proteins in Neurodegenerative Disease
Taylor, J. P., Hardy, J., & Fischbeck, K. H. (2002) · Science · doi:10.1126/science.1067122 · Cited by 1,251
Browne, S. E., Bowling, A. C., Macgarvey, U., Baik, M. J., Berger, S. C., Muquit, M. M. K., Bird, E. D., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410410514 · Cited by 885
Mitochondrial defect in Huntington's disease caudate nucleus
Gu, M., Gash, M. T., Mann, V. M., Javoy‐Agid, F., Cooper, J. M., & Schapira, A. H. V. (1996) · Annals of Neurology · doi:10.1002/ana.410390317 · Cited by 758
Kell, D. B., & Oliver, S. G. (2004) · BioEssays · doi:10.1002/bies.10385 · Cited by 535 · cited 1×
“Recently, however, it has become clear that non-hypothesis driven systems biology approaches can be used effectively in such cases (Kell, 2004; Kell and Oliver, 2004).”
BackgroundSelf-citationMetabolomics and systems biology: making sense of the soup
KELL, D. (2004) · Current Opinion in Microbiology · doi:10.1016/j.mib.2004.04.012 · Cited by 529
Self-citationDiabetes mellitus in Huntington disease
Farrer, L. A. (1985) · Clinical Genetics · doi:10.1111/j.1399-0004.1985.tb00185.x · Cited by 170 · cited 2×
“We conclude that there is likely to be a subtle but complex misregulation of amino acid metabolism in HD gene-positive individuals, which correlates with symptom status in our cross-sectional study design, suggesting a progression with time.”
BackgroundResult
Cited by
Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease
Zuccato, C., Valenza, M., & Cattaneo, E. (2010) · Physiological Reviews · doi:10.1152/physrev.00041.2009 · Cited by 848
Metabolomics: A Global Biochemical Approach to Drug Response and Disease
Kaddurah-Daouk, R., Kristal, B. S., & Weinshilboum, R. M. (2008) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094715 · Cited by 670
Chemometrics in metabolomics—A review in human disease diagnosis
Madsen, R., Lundstedt, T., & Trygg, J. (2010) · Analytica Chimica Acta · doi:10.1016/j.aca.2009.11.042 · Cited by 557
Huntington's disease: from pathology and genetics to potential therapies
Imarisio, S., Carmichael, J., Korolchuk, V., Chen, C.-W., Saiki, S., Rose, C., Krishna, G., Davies, J. E., Ttofi, E., Underwood, B. R., et al. (2008) · Biochemical Journal · doi:10.1042/bj20071619 · Cited by 409
Self-citationMetabolomic profiling to develop blood biomarkers for Parkinson's disease
Bogdanov, M., Matson, W. R., Wang, L., Matson, T., Saunders-Pullman, R., Bressman, S. S., & Beal, M. F. (2008) · Brain · doi:10.1093/brain/awm304 · Cited by 401
Metabolic Fingerprinting As A Diagnostic Tool
Ellis, D. I., Dunn, W. B., Griffin, J. L., Allwood, J. W., & Goodacre, R. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.9.1243 · Cited by 396
Self-citationGas chromatography/mass spectrometry in metabolic profiling of biological fluids
Pasikanti, K. K., Ho, P. C., & Chan, E. C. Y. (2008) · Journal of Chromatography B · doi:10.1016/j.jchromb.2008.04.033 · Cited by 302
Systems biology, metabolic modelling and metabolomics in drug discovery and development
Kell, D. B. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.10.004 · Cited by 297
Self-citationMetabolomics: A Global Biochemical Approach to the Study of Central Nervous System Diseases
Kaddurah-Daouk, R., & Krishnan, K. R. R. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.174 · Cited by 293
Current metabolomics: Practical applications
Putri, S. P., Nakayama, Y., Matsuda, F., Uchikata, T., Kobayashi, S., Matsubara, A., & Fukusaki, E. (2013) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2012.12.007 · Cited by 288
Metabolomics tools for identifying biomarkers for neuropsychiatric diseases
Quinones, M. P., & Kaddurah-Daouk, R. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.02.019 · Cited by 284
Dunn, W. B. (2008) · Physical Biology · doi:10.1088/1478-3975/5/1/011001 · Cited by 278
Self-citationAltered cholesterol and fatty acid metabolism in Huntington disease
Block, R. C., Dorsey, E. R., Beck, C. A., Brenna, J. T., & Shoulson, I. (2010) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2009.11.003 · Cited by 152
A preliminary metabolomic analysis of older adults with and without depression
Paige, L. A., Mitchell, M. W., Krishnan, K. R. R., Kaddurah‐Daouk, R., & Steffens, D. C. (2007) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1690 · Cited by 136
Biomarkers intersect with the exposome
Rappaport, S. M. (2012) · Biomarkers · doi:10.3109/1354750x.2012.691553 · Cited by 114
“Huntington’s disease Neurologic 50 15 15 (Underwood et al. 2006)”
Chiang, M.-C., Chen, H.-M., Lee, Y.-H., Chang, H.-H., Wu, Y.-C., Soong, B.-W., Chen, C.-M., Wu, Y.-R., Liu, C.-S., Niu, D.-M., et al. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddl481 · Cited by 95
Metabolomic analysis of male combat veterans with post traumatic stress disorder
Mellon, S. H., Bersani, F. S., Lindqvist, D., Hammamieh, R., Donohue, D., Dean, K., Jett, M., Yehuda, R., Flory, J., Reus, V. I., et al. (2019) · PLOS ONE · doi:10.1371/journal.pone.0213839 · Cited by 85
Spinocerebellar ataxias caused by polyglutamine expansions: A review of therapeutic strategies
Underwood, B. R., & Rubinsztein, D. C. (2008) · The Cerebellum · doi:10.1007/s12311-008-0026-z · Cited by 44
Self-citationDuarte, A. I., Sjögren, M., Santos, M. S., Oliveira, C. R., Moreira, P. I., & Björkqvist, M. (2018) · Scientific Reports · doi:10.1038/s41598-018-27121-w · Cited by 25
Metadata
- Authors
- Underwood, B. R., Broadhurst, D., Dunn, W. B., Ellis, D. I., Michell, A. W., Vacher, C., Mosedale, D. E., Kell, D. B., Barker, R. A., Grainger, D. J., & Rubinsztein, D. C.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-02-07
- Volume
- 129
- Issue
- 4
- Pages
- 877-886
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2145196491
- Cited by
- 183
- References
- 6
- FWCI
- 6.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.